Today: 1 July 2026
Browse Category

SWX:MIC 6 June 2025

Connecting Colombia: Bridging the Digital Divide from Cities to the Amazon

Connecting Colombia: Bridging the Digital Divide from Cities to the Amazon

Colombia has seen rapid growth in internet access, reaching roughly three-quarters of the population online as of 2024 Datareportal. Mobile phones and home broadband have become common in urban areas, transforming how Colombians communicate, work, and learn. However, these gains also mask stark disparities – a deep digital divide separates well-connected cities from rural and remote regions. This report provides a comprehensive overview of internet access in Colombia, including penetration rates, urban vs. rural gaps, key service providers, typical speeds and pricing, the emergence of satellite internet, government initiatives, infrastructure challenges, and future trends. The tone is informative yet accessible, aiming to shed light on both progress and ongoing challenges in connecting all corners of Colombia to the digital world. Internet usage in Colombia has grown dramatically, but there is still room to improve. As of early 2025, an estimated 41.1 million Colombians were internet users, equivalent to about 77% of the population Datareportal. The majority of users access the internet via mobile devices, but fixed broadband subscriptions have also increased. Colombia had about 17 fixed broadband subscriptions per 100 people in 2023, reflecting steady growth in home internet connectivity Theglobaleconomy. In early 2024 there were 39.5 million internet users,

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Go toTop